Product
Venetoclax + Azacitidine + HAAG regimen
1 clinical trial
2 indications
Indication
Intermediate Risk Acute Myeloid LeukemiaIndication
Acute Myeloid LeukemiaClinical trial
A Single-center, Single-arm, Prospective Clinical Study on the Efficacy and Safety of Venetoclax and Azacitidine Combined With HAAG in the Induction Treatment of Intermediate and High-risk Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-05-30